@article{ehrmann2023_91226,
  title = {Health care effects and medical benefits of a smartphone-based diabetes self-management application : study protocol for a randomized controlled trial},
  author = {Ehrmann, Dominic and Eichinger, V. and Vesper, Iris and Kober, J. and Kraus, M. and Schäfer, V. and Hermanns, Norbert and Kulzer, Bernhard and Silbermann, Stephan},
  year = {2023},
  pages = {1-8},
  publisher = {Otto-Friedrich-Universität},
  address = {Bamberg},
  urn = {urn:nbn:de:bvb:473-irb-912263},
  url = {https://fis.uni-bamberg.de/handle/uniba/91226},
  language = {eng},
  abstract = {Background:
Diabetes self-management is a mainstay of diabetes care, but the implementation of self-management regimens into daily life is complex and often results in discouragement and distress. Modern approaches such as smartphone-based self-management applications are therefore needed to support people with diabetes. Since reimbursability would increase the availability of such digital applications to people with diabetes, we designed a study that meets all scientific and methodological requirements set by the German Digital Healthcare Act to allow reimbursement for a specific application (mySugr PRO). Here, we report the protocol of this study that aims at evaluating the efficacy of the digital self-management application with regard to patient-reported outcomes and medical benefits.

Methods/design:
This multicenter, open-label, randomized, parallel-group, controlled trial will evaluate the health care effects and medical benefits of mySugr PRO. A total of 466 people with diabetes will be randomly allocated (2:1 randomization) to the interventional group (n = 311) that will use the digital self-management application during the 12-week study period or the control group (n = 155; no usage of the application). Baseline and follow-up examinations will assess diabetes distress as the primary endpoint as well as empowerment, HbA1c, blood glucose data, self-management, general well-being, and treatment satisfaction as secondary endpoints. Statistical analyses will use an intention-to-treat procedure (using multiple imputation for missing values) as well as a per-protocol approach for sensitivity analysis.

Discussion:
To the best of our knowledge, this study will be one of the largest diabetes-specific evaluations of a digital health application supporting people with diabetes in their diabetes self-management that follow the requirements of the German Digital Healthcare Act.

Trial registration:
German Clinical Trial Register DRKS00022923. Registered on 22 October 2020.},
  keywords = {Diabetes, Self-management, Diabetes distress, Digital health application}
}
